BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The BioCalendar - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The BioCalendar
X-ORIGINAL-URL:https://thebiocalendar.com
X-WR-CALDESC:Events for The BioCalendar
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20240310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20241103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251107
DTEND;VALUE=DATE:20251111
DTSTAMP:20260530T062332
CREATED:20251014T134825Z
LAST-MODIFIED:20251014T134825Z
UID:9267-1762473600-1762819199@thebiocalendar.com
SUMMARY:Scientific Sessions 2025
DESCRIPTION:Four Days. Global Experts. Limitless Discovery.\n#AHA25 is the premier global event in cardiovascular health and science offering unmatched access to groundbreaking research\, dynamic learning\, and career-defining connections. The latest discoveries are at your fingertips!
URL:https://thebiocalendar.com/event/scientific-sessions-2025/
LOCATION:New Orleans\, New Orleans\, LA\, United States
CATEGORIES:Academic Research
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251110T100000
DTEND;TZID=America/New_York:20251110T110000
DTSTAMP:20260530T062332
CREATED:20251023T140620Z
LAST-MODIFIED:20251023T140620Z
UID:9395-1762768800-1762772400@thebiocalendar.com
SUMMARY:OPCU Special Edition: Peptides & Oligos
DESCRIPTION:This interactive roundtable brought together industry experts to explore the unique challenges of outsourcing peptide drug development with CDMOs and CMOs. The conversation highlights critical pain points across the development journey\, including: \n– Synthesis & Scale-Up: The technical complexity of moving from lab-scale peptide synthesis to commercial volumes while managing yield\, purity\, and cost.\n– Analytical Hurdles: The difficulty of establishing robust testing methods for increasingly complex peptides\, from characterization and stability to impurity profiling.\n– Regulatory Requirements: How evolving global expectations demand early alignment between sponsors and outsourcing partners to avoid costly delays. \nParticipants share best practices for effective CDMO collaboration\, lessons on pitfalls to avoid\, and emerging innovations reshaping the outsourcing landscape\, such as advances in continuous flow synthesis\, new analytical platforms\, and strategies for improving scalability and compliance.
URL:https://thebiocalendar.com/event/opcu-special-edition-peptides-oligos/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/10/11-2025-OPCU-1280x720-1-scaled.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251110T110000
DTEND;TZID=America/New_York:20251110T120000
DTSTAMP:20260530T062332
CREATED:20251023T132525Z
LAST-MODIFIED:20251023T132525Z
UID:9307-1762772400-1762776000@thebiocalendar.com
SUMMARY:Boosting Vaccine Yields Through Smarter Cell Culture Media Optimization
DESCRIPTION:The optimization of cell culture media is a critical factor in achieving efficient and reliable vaccine production. Among the key components\, peptones have demonstrated significant potential in enhancing cell growth\, viability\, and productivity. In this webinar\, we will explore the impact of peptones on vaccine manufacturing\, with a focus on their role in improving performance across multiple cell lines\, including HEK293 and BHK-21. Through case examples and data-driven insights\, attendees will gain an understanding of how tailored peptone supplementation can boost yield\, streamline processes\, and support consistent vaccine production.  \nJoin us to learn how strategic use of peptones can help overcome productivity challenges and contribute to more efficient biomanufacturing outcomes.
URL:https://thebiocalendar.com/event/boosting-vaccine-yields-through-smarter-cell-culture-media-optimization/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/10/11-10-25-Thermo-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251110T130000
DTEND;TZID=America/New_York:20251110T140000
DTSTAMP:20260530T062332
CREATED:20251023T132032Z
LAST-MODIFIED:20251023T132032Z
UID:9301-1762779600-1762783200@thebiocalendar.com
SUMMARY:Choosing the Right Sporicide: Critical Factors for Robust Cleanroom Contamination Control
DESCRIPTION:In addition to basic chemicals and formulation\, there are other criteria that contribute to making something an effective and optimal sporicide. The requirements for selecting an agent or replacing an existing sporicide for use within the clean room facility should consider several key factors. \nThis webinar\, presented by Professor Tim Sandle\, PhD in partnership with Ecolab Life Sciences walks us through a number of these requirements with the intention that understanding them and seeking optimisation can ultimately lead to a more robust and efficacious use of sporicides in your facility.
URL:https://thebiocalendar.com/event/choosing-the-right-sporicide-critical-factors-for-robust-cleanroom-contamination-control/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/10/11-10-25-Ecolab-eblast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20251111T080000
DTEND;TZID=UTC:20251112T170000
DTSTAMP:20260530T062332
CREATED:20250823T010307Z
LAST-MODIFIED:20250823T010307Z
UID:8974-1762848000-1762966800@thebiocalendar.com
SUMMARY:Global Pharma and Biotech Summit
DESCRIPTION:
URL:https://thebiocalendar.com/event/global-pharma-and-biotech-summit/
LOCATION:London\, London\, United Kingdom
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251112T100000
DTEND;TZID=America/New_York:20251112T110000
DTSTAMP:20260530T062332
CREATED:20251023T131822Z
LAST-MODIFIED:20251023T131822Z
UID:9297-1762941600-1762945200@thebiocalendar.com
SUMMARY:Rethinking effectiveness in clinical operations: balancing tradeoffs in an era of disruption
DESCRIPTION:In an era of rapid disruption and technological advancement\, clinical operations leaders face mounting pressure to deliver greater effectiveness while navigating complex trade-offs. This webinar explores how organizations are rethinking their clinical operating models—balancing innovation\, efficiency\, and strategic decision-making. Join industry experts as we unpack the latest trends\, challenges\, and opportunities shaping the future of clinical operations. \nUnderstand the R&D operating model choices in pharma. \nExplore how different structural approaches — functional vs. Asset-based\, outsourced vs. in-house — are impacting clinical effectiveness\, agility\, and decision-making. \nEvaluate efficiency tradeoffs across operating models. \nAnalyze the implications of various approaches and digitalisation disruptions to clinical operations efficiency\, including speed\, cost\, quality\, and scalability.
URL:https://thebiocalendar.com/event/rethinking-effectiveness-in-clinical-operations-balancing-tradeoffs-in-an-era-of-disruption/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/10/11-12-25-PA-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251112T110000
DTEND;TZID=America/New_York:20251112T120000
DTSTAMP:20260530T062332
CREATED:20251023T131328Z
LAST-MODIFIED:20251023T131332Z
UID:9287-1762945200-1762948800@thebiocalendar.com
SUMMARY:Streamlining Biotherapy QC: Practical Solutions for Protein Analytics & Residual DNA Testing
DESCRIPTION:Biologic therapies are transforming healthcare\, but their complexity brings unique challenges for downstream quality control (QC). Ensuring product purity\, safety\, and consistency requires precise and reliable analytical methods\, especially in the face of regulatory scrutiny. Two critical areas of focus are HPLC protein analytics and residual DNA testing\, both of which present technical hurdles that can delay production timelines if not addressed effectively. \nThis webinar will explore the most common QC bottlenecks encountered during downstream biotherapy manufacturing\, with a practical lens on HPLC protein analytics and residual DNA testing. We’ll highlight common pitfalls\, debunk myths\, and offer strategies to improve robustness and reproducibility. \nParticipants will gain insight into how proactive QC planning—rather than reactive troubleshooting—can help streamline biotherapeutic development\, reduce compliance risks\, and ultimately accelerate the path to market.
URL:https://thebiocalendar.com/event/streamlining-biotherapy-qc-practical-solutions-for-protein-analytics-residual-dna-testing/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/10/11-12-25-Thermo-eBlast-700x200-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251112T110000
DTEND;TZID=America/New_York:20251112T120000
DTSTAMP:20260530T062332
CREATED:20251023T131637Z
LAST-MODIFIED:20251023T131637Z
UID:9293-1762945200-1762948800@thebiocalendar.com
SUMMARY:Driving Robust Tech Transfer in Biologics: Computational Fluid Dynamics (CFD) Simulation
DESCRIPTION:Biopharmaceutical development requires a clear understanding of how process conditions affect product quality. For therapeutic antibodies\, preserving biological activity—such as antigen binding and effector functions—depends on precise control of cell culture environments. Traditional scale-up metrics like power per volume (P/V)\, however\, often fall short when processes are transferred across facilities or equipment scales. \nIn this webinar\, we will demonstrate how Computational Fluid Dynamics (CFD) provides actionable insights into hydrodynamic and mass transfer environments that directly impact critical quality attributes (CQAs). By modeling key process attributes (KPAs)—including mixing\, shear stress\, and oxygen transfer\, CFD strengthens the Quality by Design (QbD) framework and improves process robustness. Case studies will illustrate how CFD accelerates tech transfer and supports “what-if” scenario analyses\, enabling more informed decision-making and streamlined process development.
URL:https://thebiocalendar.com/event/driving-robust-tech-transfer-in-biologics-computational-fluid-dynamics-cfd-simulation/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/10/11-12-25-Samsung-eblast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251112T110000
DTEND;TZID=America/New_York:20251112T120000
DTSTAMP:20260530T062332
CREATED:20251023T135331Z
LAST-MODIFIED:20251023T135331Z
UID:9371-1762945200-1762948800@thebiocalendar.com
SUMMARY:Unlocking The Future: Innovations in the mRNA & Oligo Supply Chains
DESCRIPTION:Join us on Wednesday\, November 12th for a forward-looking event exploring the current and next generation of raw materials shaping the mRNA and oligo therapeutics landscapes. This event will bring together industry leaders to discuss advancements in raw materials\, including novel enzymes\, optimized capping reagents\, and other essential materials. We will look at how the current generations of materials are informing the quality of our mRNA and oligo products\, while also exploring how each sector of the RNA industry is working with next-gen raw materials to reduce COGS and improve manufacturing efficiency\, product quality\, and supply chain resilience.
URL:https://thebiocalendar.com/event/unlocking-the-future-innovations-in-the-mrna-oligo-supply-chains/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/10/Untitled-design-45.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251112T160000
DTEND;TZID=America/New_York:20251112T183000
DTSTAMP:20260530T062332
CREATED:20251023T172313Z
LAST-MODIFIED:20251023T172313Z
UID:9415-1762963200-1762972200@thebiocalendar.com
SUMMARY:BVS and BioMed Realty Biotech Community Event at 650 E. Kendall St\, Cambridge
DESCRIPTION:We are very excited to invite you to the BVS and BioMed Realty Biotech Community Event in Cambridge! \nMark your calendars for a great opportunity to connect with industry leaders\, explore innovative products\, and mingle with fellow professionals in the biotech community. \nThe event will be held at 650 East Kendall Street and all the tenants in the surrounding buildings\, plus all the Biotech/Pharma companies in Cambridge/Boston are invited to attend. \n✨ What to Expect: \n    Vendor Exhibit: Discover a diverse range of exhibitors showcasing cutting-edge technology and services in the biotech space.\n    Networking Opportunities: Engage with fellow industry experts\, forge new connections\, and exchange ideas that could shape the future of biotech.\n    Delicious Food & Drinks: Enjoy delicious food & refreshments as you network and explore the vendor exhibits. \nThis is a wonderful chance for everyone to come together\, share insights\, and celebrate the vibrant biotech landscape in our region. \nAdmission Details:\nFREE for life science job-related employees (including researchers\, scientists\, purchasing\, clinical\, manufacturing\, etc.) from life science companies and research institutes.\n$200 fee for product and service providers who sell to the life science community (e.g. BVS suppliers\, business development/sales\, marketing\, lawyers\, consultants)\, which includes access to the event but does not include an exhibitor table. Exhibitor tables can be purchased separately. \nFor exhibitor tables\, please visit our website and register at: https://bvsconnection.com/events \nWe look forward to seeing you there!
URL:https://thebiocalendar.com/event/bvs-and-biomed-realty-biotech-community-event-at-650-e-kendall-st-cambridge/
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2025/10/Biotech-Event-Flyer-11-12-25.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251113
DTEND;VALUE=DATE:20251115
DTSTAMP:20260530T062332
CREATED:20250215T051803Z
LAST-MODIFIED:20250215T051822Z
UID:7226-1762992000-1763164799@thebiocalendar.com
SUMMARY:5th Investigator-Initiated Trials Summit
DESCRIPTION:As investigator-initiated trials grow more intricate\, your team needs the most up-to-date strategies on building successful IITs\, forecasting budgets\, achieving study milestones\, and brainstorming innovative KPI strategies. Save the date for November 13-14 for DGE’s 5th Investigator Initiated Trials conference! Back by popular demand\, our all-new agenda provides answers to your most urgent questions about the best practices for reviewing\, selecting\, and funding research investigators! \nThis conference had so many great takeaways. All the speakers’ candor and transparency really helped to move the field and agenda forward. I learned so much about how industry views and conducts IITs.” – Thomas Jefferson University \n“Attending the 4th Investigator Initiated Trials Summit presents an invaluable opportunity to gain insights into IIT programs across academia\, healthcare\, and industry. The summit facilitates networking with peers\, fostering the exchange of experiences\, challenges\, and best practices within the Investigator Initiated Research landscape.” – Hackensack Meridian Health
URL:https://thebiocalendar.com/event/5th-investigator-initiated-trials-summit/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/02/5th-Investigator-Initiated-Trials-Summit.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251113T080000
DTEND;TZID=America/Los_Angeles:20251113T120000
DTSTAMP:20260530T062332
CREATED:20251029T225142Z
LAST-MODIFIED:20251029T225251Z
UID:9425-1763020800-1763035200@thebiocalendar.com
SUMMARY:Gray\, Gray & Gray Year End Planning Seminar - Straight Talk on Taxes\, Tariffs & Trends
DESCRIPTION:2025 Year End Planning Seminar Registration\n\n\n\n\n\n\n\n\n\n\n\nRegister now for Gray\, Gray & Gray’s Year End Planning Seminar on Thursday\, November 13th! \nIn-Person: Gray\, Gray & Gray’s Canton Office\n150 Royall Street\nCanton\, MA 02021 \n  \nRegistration\, Breakfast & Networking: 8:00 am – 9:00 am\nSeminar Sessions: 9:00 am – 12:00 pm
URL:https://thebiocalendar.com/event/gray-gray-gray-year-end-planning-seminar-straight-talk-on-taxes-tariffs-trends/
LOCATION:Canton\, Canton\, MA\, 02021\, United States
CATEGORIES:Seminar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251113T090000
DTEND;TZID=America/Los_Angeles:20251113T120000
DTSTAMP:20260530T062332
CREATED:20251008T125302Z
LAST-MODIFIED:20251008T125302Z
UID:9252-1763024400-1763035200@thebiocalendar.com
SUMMARY:Regional Biotechnology Conference
DESCRIPTION:The Regional Biotechnology Conference is an annual conference that attracts more than 100 of the region’s movers and shakers for a half-day of dynamic speakers and topics that are important to start-up and early stage biotech company leaders. This year’s conference will feature keynote speakers\, Nicholas A. Siciliano\, Ph.D.\, CEO of Vittoria Biotherapeutics. The afternoon will include a Health Equity panel of experts!
URL:https://thebiocalendar.com/event/regional-biotechnology-conference-3/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/10/2025-RBC-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251113T110000
DTEND;TZID=America/New_York:20251113T120000
DTSTAMP:20260530T062332
CREATED:20251023T135638Z
LAST-MODIFIED:20251023T135638Z
UID:9375-1763031600-1763035200@thebiocalendar.com
SUMMARY:Viability On The Line: Defining Minimum Quality For CGT Raw Materials
DESCRIPTION:The minimum-viable-product concept was born not in advanced therapy\, but in the tech sector. It asks: What’s the smallest set of materials or features required to achieve the desired outcome? This principle can be a powerful guide when sourcing raw materials for gene therapy.  \nExecutive Editor Jon O’Connell hosts this Cell & Gene Live event\, exploring whether minimum viability can help gene therapy developers make smarter sourcing decisions — from research-grade production through clinical and commercial phases\, where cost and quality can make or break a product. \nExperts Yan Zhi\, Ph.D.\, a director and product manager at CSL Behring\, and Lawrence Thompson\, Ph.D.\, an associate research fellow at Pfizer\, will talk about sourcing and outsourcing decisions in the context of product quality\, risk\, and financial strategy. This is more than phase-appropriate supply chain strategies. Join us for an interactive discussion to unpack viability at the individual raw material level and the product candidate level.
URL:https://thebiocalendar.com/event/viability-on-the-line-defining-minimum-quality-for-cgt-raw-materials/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/10/11-13-25-CGL-HTML-600x300-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251114T110000
DTEND;TZID=America/New_York:20251114T120000
DTSTAMP:20260530T062332
CREATED:20251023T134718Z
LAST-MODIFIED:20251023T134718Z
UID:9365-1763118000-1763121600@thebiocalendar.com
SUMMARY:Next-Gen analytics for mRNA and LNPs: when traditional methods fall short
DESCRIPTION:Following the first mRNA-LNP based Covid-19 vaccines\, a plethora of new modalities were invented that are directed to treating and preventing diseases in previously unimaginable ways. With these new modalities\, both in the field of XNA and their encapsulating modalities (Lipid Nano Particles) standard methods fall short\, lacking the resolution\, specificity\, and adaptability needed to characterize these advanced molecules. In this webinar\, we’ll uncover the hidden challenges in analyzing next-generation RNA and LNP therapies\, and explore how Lonza is pioneering advanced\, fit-for-purpose analytics to meet the demands of this fast-moving field.
URL:https://thebiocalendar.com/event/next-gen-analytics-for-mrna-and-lnps-when-traditional-methods-fall-short/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/10/11-14-25-Lonza-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251115
DTEND;VALUE=DATE:20251120
DTSTAMP:20260530T062332
CREATED:20251022T172537Z
LAST-MODIFIED:20251022T172537Z
UID:9285-1763164800-1763596799@thebiocalendar.com
SUMMARY:Neuroscience 2025
DESCRIPTION:Join Us in San Diego for Neuroscience 2025!\n\n  \nMeeting Dates: Saturday\, November 15–Wednesday\, November 19\n \nLocation: San Diego Convention Center \nWe must continue to do the important work of science\, including submitting grants and conducting research. Our work is vital to the health and well-being of all people\, and as researchers and members of SfN you play a crucial role in furthering our field and promoting a healthy scientific enterprise. \n  \nTaconic Biosciences will attend the Society for Neuroscience (SfN) 2025 Annual Meeting in San Diego. Visit Booth #2512 to learn how our comprehensive portfolio of neuroscience models enable studies in neurodegeneration\, neuroinflammation\, and complex brain-immune interactions.
URL:https://thebiocalendar.com/event/neuroscience-2025/
LOCATION:San Diego\, San Diego\, CA\, United States
CATEGORIES:Academic Research
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251117
DTEND;VALUE=DATE:20251121
DTSTAMP:20260530T062332
CREATED:20250721T234821Z
LAST-MODIFIED:20250721T234821Z
UID:8505-1763337600-1763683199@thebiocalendar.com
SUMMARY:MEDICA
DESCRIPTION:From 17 to 20 November 2025\, MEDICA will once again gather international experts from the medical industry in Düsseldorf\, Germany. \nWith over 5\,000 exhibitors from 72 countries and 80\,000 visitors MEDICA in Düsseldorf is one of the largest medical B2B trade fairs in the world. It offers a central stage for innovative products and services from the fields of medical imaging\, laboratory technology\, diagnostics\, health IT\, mobile health as well as physiotherapy/orthopaedic technology and medical consumables. The extensive programme of first-class forums\, conferences and special shows provides opportunities for interesting presentations and discussions with experts and politicians and also includes pitches of new products and award ceremonies.
URL:https://thebiocalendar.com/event/medica/
LOCATION:Dusseldorf\, Düsseldorf\, North Rhine-Westphalia\, 40547\, Germany
CATEGORIES:Summit,Trade Show
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251117T110000
DTEND;TZID=America/New_York:20251117T120000
DTSTAMP:20260530T062332
CREATED:20251023T134448Z
LAST-MODIFIED:20251023T134448Z
UID:9357-1763377200-1763380800@thebiocalendar.com
SUMMARY:Advancing Topical Formulations with Innovative Preclinical Models
DESCRIPTION:A limited proportion of drug candidates ultimately achieve regulatory approval\, often due to challenges such as insufficient efficacy\, safety concerns\, complex or poorly understood targets\, limitations in predictive preclinical models\, or commercial viability issues. Given the significant cost and time associated with development\, early identification of promising candidates and the implementation of a robust development strategy aligned with current quality standards are critical to improving success rates. \nComprehensive drug characterization and preformulation strategies should be employed to assess drug formulatability. Within this approach different models\, whether in-silico/mathematical models or in vitro/ex-vivo can be used to screen between different drugs and drug products to select the candidate with the highest chance of success. A sound formulation development approach with full consideration of the drug\, the patient and regulatory pathway should include the appropriate in vitro/ex vivo models to de-risk the program prior to clinical studies. \nA robust formulation development approach integrates robust scientific principles\, systematic formulation development and innovative preclinical models to facilitate early identification of candidates with poor developability. This enables more informed decision-making and supports the advancement of viable drug candidates while mitigating downstream development risks.
URL:https://thebiocalendar.com/event/advancing-topical-formulations-with-innovative-preclinical-models/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/10/11-17-25-MedPharm-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251118
DTEND;VALUE=DATE:20251121
DTSTAMP:20260530T062332
CREATED:20250523T205254Z
LAST-MODIFIED:20250523T205636Z
UID:8160-1763424000-1763683199@thebiocalendar.com
SUMMARY:Copay\, Reimbursement and Access Congress
DESCRIPTION:With increased complexity and nuance\, the need for innovative copay and reimbursement strategies is now. Copay\, Reimbursement and Access Congress is bringing together seasoned experts this November to deliver the most up-to-date insights necessary to enhance patient affordability\, ensure program sustainability and navigate the regulatory landscape. Remaining compliant has never been more complex and program innovation has never been more important – Do not miss your opportunity to connect with influential leaders\, gain valuable insights and expand your network. \nMention 25B4B10 to save 10%
URL:https://thebiocalendar.com/event/copay-reimbursement-and-access-congress-4/
LOCATION:Hilton East Brunswick Hotel\, East Brunswick\, NJ\, United States
CATEGORIES:Networking,Symposium
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2025/05/Copay_600x200-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20251118T080000
DTEND;TZID=UTC:20251120T170000
DTSTAMP:20260530T062332
CREATED:20250813T014712Z
LAST-MODIFIED:20250813T014712Z
UID:8835-1763452800-1763658000@thebiocalendar.com
SUMMARY:Pharma/Biotech Gross-To-Net Summit
DESCRIPTION:Optimize Your Gross-To-Net Strategies to Drive Financial Excellence \n\nSave 10% today with VIP code: 25B4B10* \nThe Pharma/Biotech GTN Summit\, taking place November 18-20\, 2025 in Philadelphia\, PA\, is a CPE accredited conference designed to equip pharmaceutical and biotech finance professionals with proven methodologies\, forecasting models\, and automation insights to enhance visibility\, profitability\, and control in gross-to-net management. \n\nWhether your organization is preparing for commercial revenue or managing large product portfolios\, the Pharma/Biotech GTN Summit delivers tailored discussions and solutions to address your unique challenges and help you optimize your GTN processes. \n\nStay at the leading edge of GTN excellence with the latest policy updates\, technology integrations\, market access insights and pricing optimizations – all in one place! \n250+ of your peers will be there. Join us! \nSee the agenda to discover why this year’s conference is a must-attend and secure your spot today. \n  \n  \n  \n  \n*Terms & Conditions Discount Promotion:\n1. Discounts not to be used in conjunction with any other discount.\n2. Discount codes not applicable to pre-existing bookings.\n3. Training course add-on to be purchased in conjunction with a full conference pass only. \n 
URL:https://thebiocalendar.com/event/pharma-biotech-gross-to-net-summit/
LOCATION:Philadelphia\, Philadelphia\, PA\, United States
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251118T110000
DTEND;TZID=America/New_York:20251118T120000
DTSTAMP:20260530T062332
CREATED:20251023T134126Z
LAST-MODIFIED:20251023T134126Z
UID:9349-1763463600-1763467200@thebiocalendar.com
SUMMARY:EU GMP Annex 11 action plan: Assessment\, strategy and digital solutions for compliance
DESCRIPTION:Join Stephen Ferrell\, Chief Product Officer at Valkit.ai as he provides a critical analysis of one of the most significant regulatory updates to impact pharmaceutical computerized systems in over a decade. The proposed EU GMP Annex 11 revision transforms European compliance requirements from risk-based guidance to prescriptive technical specifications\, introducing mandatory audit trails for all user interactions\, comprehensive cybersecurity frameworks and detailed electronic signature protocols that could affect 60-80% of existing pharmaceutical systems globally. \nStephen will explore the key contradictions and implementation challenges within the proposed regulations\, compare them with FDA 21 CFR Part 11 and ICH guidelines\, and examine how these changes position EU requirements as the emerging global standard for pharmaceutical computerised system compliance. Drawing on his extensive experience as a GAMP 5 contributing author\, he’ll provide practical insights for life science organizations helping you to develop strategic compliance roadmaps that balance regulatory adherence with operational efficiency. \nThis webinar will demonstrate how modern\, integrated digital quality management platforms like Ideagen Quality Management can address these evolving regulatory demands while enabling pharmaceutical innovation. Attendees will gain actionable strategies for navigating the 3-5 year industry-wide implementation timeline\, understanding the technical and business implications of the changes and building future-ready validation programs that accommodate regulatory evolution while maintaining competitive advantage in the global pharmaceutical market. \nKey Learning Objectives:
URL:https://thebiocalendar.com/event/eu-gmp-annex-11-action-plan-assessment-strategy-and-digital-solutions-for-compliance/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/10/11-18-25-Ideagen-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251118T110000
DTEND;TZID=America/New_York:20251118T120000
DTSTAMP:20260530T062332
CREATED:20251023T134239Z
LAST-MODIFIED:20251023T134239Z
UID:9353-1763463600-1763467200@thebiocalendar.com
SUMMARY:The future is now: are you keeping pace with oligo synthesis optimization?
DESCRIPTION:The oligonucleotide market is moving fast. Now is an exciting time with 20 therapeutics on the market and so many oligos being developed for future treatments. While the market traditionally centred around the outstanding and essential work with rare diseases\, some blockbusters are emerging for much larger patient indications. \nWe know that you’re the expert in your molecule and have the ambition to advance healthcare and treat your patients. At Cytiva\, we have four decades of experience and expertise in oligonucleotide manufacturing\, and our prior knowledge and process experience could make a difference for your in-house R&D\, process development\, and scale-up. We can also help if you want to move your process in-house from a CDMO. In this presentation\, we’ll share some of our key learnings and recent innovations that can help you optimize resource use and future RNA synthesis.
URL:https://thebiocalendar.com/event/the-future-is-now-are-you-keeping-pace-with-oligo-synthesis-optimization/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/10/11-18-25-Cytiva-eblast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251120T080000
DTEND;TZID=America/Los_Angeles:20251121T170000
DTSTAMP:20260530T062332
CREATED:20250902T214542Z
LAST-MODIFIED:20250902T214542Z
UID:9158-1763625600-1763744400@thebiocalendar.com
SUMMARY:Patient Support Services Congress
DESCRIPTION:This congress is designed to help educate and share innovative program design\, latest customer strategies and practical solutions to overcome complex barriers\, enhance program performance and deliver best-in-class patient programs amidst evolving regulations. Compliance and Operations teams unite at Patient Support Services Congress for next-level benchmarking to drive program success. Benefit from collaborative sessions as well as individualized tracked content and walk away with everything you need to propel your program forward. \n \n 
URL:https://thebiocalendar.com/event/patient-support-services-congress-3/
LOCATION:East Brunswick\, NJ
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251120T110000
DTEND;TZID=America/New_York:20251120T120000
DTSTAMP:20260530T062332
CREATED:20251016T171710Z
LAST-MODIFIED:20251023T131111Z
UID:9274-1763636400-1763640000@thebiocalendar.com
SUMMARY:Unpacking pDNA processes: Capacity\, complexity\, and cutting-edge solutions (FREE WEBINAR)
DESCRIPTION:As the demand for plasmid DNA (pDNA) continues to surge across gene therapies\, mRNA vaccines\, and cell therapies\, manufacturers are facing growing pressure to expand capacity with speed and precision. But scaling pDNA production is far from straightforward. Unforeseen complexities in areas like facility design or process innovation often leads to costly delays and missed opportunities. \nIn this expert-led panel discussion\, industry leaders from Cytiva\, Bionova\, and other innovators will unpack the evolving landscape of pDNA manufacturing. You’ll gain insights into key trends driving therapeutic demand\, common missteps in capacity planning\, and how modular\, flexible facility design can accelerate GMP readiness. The panel will also spotlight exciting process innovations in fermentation\, purification\, and analytics—plus offer candid perspectives on the biggest challenges and opportunities shaping the future of the pDNA industry. \nWhether you’re entering the pDNA space or preparing for scale up\, this session will offer actionable strategies to help you navigate the road ahead.
URL:https://thebiocalendar.com/event/unpacking-pdna-processes-capacity-complexity-and-cutting-edge-solutions-free-webinar/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/10/Untitled-design-43.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251120T160000
DTEND;TZID=America/New_York:20251120T190000
DTSTAMP:20260530T062332
CREATED:20251023T171726Z
LAST-MODIFIED:20251110T180918Z
UID:9407-1763654400-1763665200@thebiocalendar.com
SUMMARY:BVS’ Biotech Innovation & Vendor Expo at the Cambridge Marriott
DESCRIPTION:We are very excited to announce our indoor Biotech Innovation & Vendor Expo at the Cambridge Marriott. \nMark your calendars for a great opportunity to connect with industry leaders\, explore innovative products\, and mingle with fellow professionals in the biotech community. \nThis biotech community event will bring together researchers from local biotech/pharma accounts in Cambridge/Boston and the surrounding areas to see the latest in tools\, technologies\, and equipment to help advance life science research. \n✨ What to Expect: \n    Vendor Exhibits: Discover a diverse range of exhibitors showcasing cutting-edge technology and services in the biotech space.\n    Networking Opportunities: Engage with fellow industry experts\, forge new connections\, and exchange ideas that could shape the future of biotech.\n    Delicious Food and Drinks: Enjoy delicious food and drinks s as you network and explore the vendor exhibits. \nAdmission Details:\nFREE for life science job-related employees (including researchers\, scientists\, purchasing\, clinical\, manufacturing\, etc.) from life science companies and research institutes.\n$250 fee for product and service providers who sell to the life science community (e.g. BVS suppliers\, business development/sales\, marketing\, lawyers\, consultants)\, which includes access to the event but does not include an exhibitor table. Exhibitor tables can be purchased separately. \nFor exhibitor tables\, please visit our website and register at: https://bvsconnection.com/events \nPlease feel free to invite others in the community that could benefit from attending. \nWe look forward to seeing you there!
URL:https://thebiocalendar.com/event/bvs-innovation-symposium-vendor-expo-in-cambridge/
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2025/10/SYMPOSIUM-Vendor-flyer-11-20-25.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251121T180000
DTEND;TZID=America/Los_Angeles:20251121T210000
DTSTAMP:20260530T062332
CREATED:20251121T193142Z
LAST-MODIFIED:20251121T193142Z
UID:9565-1763748000-1763758800@thebiocalendar.com
SUMMARY:STAT@JPM: Health Care at a Crossroads
DESCRIPTION:Never has so much been at stake when it comes to investments in health care. All kinds of uncertainty — political\, social\, and scientific — stand between new preventatives\, treatments\, and cures and the patients who need them. But never has investment been more important either. Join us for a look at what is at stake\, what is ahead\, and ideas for developing new medicines in 2026. \nFeatured Speakers \n\nYvonne Greenstreet\, M.D.\, MBA\, OBE\, chief executive officer\, Alnylam Pharmaceuticals\nAgustin Mohedas\, Ph.D.\, portfolio manager\, research analyst\, Janus Henderson Investments\nRoderick Wong\, M.D.\, managing partner\, chief investment officer\, RTW\nTeresa Graham\, chief executive officer\, Roche Pharmaceuticals (sponsor speaker)
URL:https://thebiocalendar.com/event/statjpm-health-care-at-a-crossroads/
LOCATION:San Francisco\, CA\, San Francisco\, CA\, United States
CATEGORIES:Forum
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251201T110000
DTEND;TZID=America/Los_Angeles:20251201T120000
DTSTAMP:20260530T062332
CREATED:20251104T142351Z
LAST-MODIFIED:20251104T142351Z
UID:9433-1764586800-1764590400@thebiocalendar.com
SUMMARY:The Science of CRO Selection: Insights from $2B+ in Vendor Selections
DESCRIPTION:Selecting the right CRO is one of the most critical decisions in clinical development\, yet rarely a straightforward one. Sponsors often find that comparing CRO proposals isn’t an apples-to-apples exercise — with variations in assumptions\, timelines\, and resource structures making true comparisons difficult. \nThis session draws on insights from more than $2B in CRO selections facilitated through the Clin.AI platform\, showing how sponsors can bring structure and transparency to the process. We’ll discuss how the RFP should serve not just as a budget exercise\, but as a strategic opportunity to evaluate timelines\, resources\, and operational readiness — while engaging internal stakeholders and aligning expectations early. \nUltimately\, the goal is to help sponsors identify the right cultural and operational fit — a partner who can execute efficiently\, manage risk\, and deliver on time and within budget.
URL:https://thebiocalendar.com/event/the-science-of-cro-selection-insights-from-2b-in-vendor-selections/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/11/12-01-25-ClinAI-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251202T080000
DTEND;TZID=America/Los_Angeles:20251202T113000
DTSTAMP:20260530T062332
CREATED:20251125T142613Z
LAST-MODIFIED:20251125T142613Z
UID:9582-1764662400-1764675000@thebiocalendar.com
SUMMARY:Philadelphia Life Sciences Conference
DESCRIPTION:Greater Philadelphia sits at the forefront of a dynamic life sciences evolution\, where strategic decision-making today will shape the trajectory of the region’s biotech and innovation economy for years to come. As funding landscapes shift\, groundbreaking research emerges\, and tenant demands evolve\, stakeholders across commercial real estate\, including developers\, investors\, and brokers\, need critical insights to navigate the complex marketplace. \nPhiladelphia boasts robust research institutions\, cutting-edge talent\, and a collaborative ecosystem uniquely positioned to nurture startups into thriving enterprises. But retaining these innovative companies locally demands strategic investment and thoughtfully designed infrastructure. This event provides essential guidance on fostering a robust “bench-to-market” pipeline\, securing creative financing amid challenging market conditions\, and capitalizing on opportunities poised to reshape the region. \nJoin industry leaders\, innovators\, and policymakers as they delve deep into strategies for attracting and retaining tenants\, leveraging financial tools\, and building the resilient and adaptive infrastructure needed for Philadelphia’s sustained growth in life sciences real estate. \nWhat You Will Learn: \n\nPhiladelphia’s “Secret Sauce” for Startups: The city offers a unique blend of assets for life science entrepreneurs – world-class research institutions producing cutting-edge IP and talent\, plus a culture of collaboration where academia\, industry\, and government actively work together. Hear how this has created fertile ground for startups. For instance\, the University City Science Center’s expansion with Wexford and Ventas now spans 11 city blocks and houses 200+ companies\, providing critical lab space and networking for entrepreneurs. We’ll hear success stories of companies that started in a campus lab or incubator and grew into standalone firms\, illustrating the “incubation-to-graduation” pipeline now established in Philly .\nRetaining Homegrown Companies: What does it takes to keep companies in the region through their growth stages. Philadelphia’s “bench-to-market” pathway is increasingly robust\, a company can start at a university lab\, launch at a BioLabs or B+Labs incubator\, then move up to a larger space in the city\, and even establish manufacturing at sites like the Navy Yard\, all without leaving Greater Philadelphia . This continuum (rare among cities) is a selling point. Hear how to leverage initiatives and how to address any gaps so that Philly’s brightest biotech companies scale up locally rather than relocate.\nCapital Markets and Development Strategy: Higher interest rates and cautious lenders have forced developers to be more strategic\, often requiring pre-leases for new projects. Experts will share how they are securing financing\, using creative tools (C-PACE\, JV partnerships) and timing projects to ride out the storm .\nPhiladelphia’s Competitive Edge: Highlight fundamentals keeping Philly on top – huge research institutions and NIH funding\, a rise in lab rents in University City\, and abundant STEM talent. These factors\, plus a cost advantage\, position the region to rebound strongly as confidence returns.\nDeveloper Financing Strategies in a Tight Market: With traditional debt financing more expensive\, developers have had to get creative to fund projects. Panelists will share firsthand experiences structuring deals\, (including C-PACE and regional bank loans) amid a tough lending environment. Examine how life science projects can leverage public sector support and how some developers are deferring or phasing projects to align with capital availability.\nOpportunities on the Horizon: Despite the current caution\, Philadelphia’s fundamentals continue to attract interest. Are developers quietly assembling capital to pounce on distressed lab assets or conversions at a discount? Will the suburban markets (with their lower costs and existing pharma infrastructure) see a faster revival? And how can public initiatives be leveraged to catalyze public-private investment in new research facilities or workforce training centers?
URL:https://thebiocalendar.com/event/philadelphia-life-sciences-conference/
LOCATION:Philadelphia\, Philadelphia\, PA\, United States
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251202T080000
DTEND;TZID=America/Los_Angeles:20251202T120000
DTSTAMP:20260530T062332
CREATED:20251125T142457Z
LAST-MODIFIED:20251125T142457Z
UID:9581-1764662400-1764676800@thebiocalendar.com
SUMMARY:2025 Boston Biotech Summit
DESCRIPTION:What You’ll Learn: \n\nHow will lower interest rates influence biotech funding\, investment flows\, and real estate capital allocation in 2025?\nWith a record volume of new lab and GMP supply delivering this year\, how can owners make their assets stand out in a crowded market?\nIs renewed activity in biotech IPOs and venture funding a sign of sustained momentum heading into 2026?\nHow is Boston’s biotech ecosystem continuing to foster innovation\, and what distinctive advantages will support its rebound?\nWhat impact have major development projects across Greater Boston had on advancing the region’s life sciences growth and competitiveness?\nAs vacancy climbs above 30% in Greater Boston\, is the balance of power shifting further toward tenants\, and what will they expect from new space?\nHow is technology driving the demand for flexible\, adaptable labs and GMP facilities that can evolve with science?\nIn what ways has tenant demand for modular layouts\, spec suites\, and shorter lease terms reshaped leasing dynamics in 2025?\nWhy is biomanufacturing becoming a stabilizing force for the market\, and how are GMP facilities attracting both tenants and investors?\n\nHow you’ll do more business: \nConnect with industry leaders to explore emerging leasing dynamics\, gain valuable investor insights and discover cutting-edge innovations in workspace design. Gain insights into the trade-offs and advantages associated with advanced manufacturing techniques and Good Manufacturing Practice\, or GMP\, standards in biotech. Explore topics like sustainable facility design\, power solutions\, access considerations and other crucial aspects that can enhance your business strategy.  \nWho attends: \nInvestors\, owners\, developers\, tenants\, end users\, brokers\, lawyers\, designers\, contractors\, architects\, property managers and more!
URL:https://thebiocalendar.com/event/2025-boston-biotech-summit/
LOCATION:Somerville\, Somerville\, MA\, United States
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251202T110000
DTEND;TZID=America/Los_Angeles:20251202T120000
DTSTAMP:20260530T062332
CREATED:20251106T150004Z
LAST-MODIFIED:20251106T150004Z
UID:9444-1764673200-1764676800@thebiocalendar.com
SUMMARY:Streamline the Critical Path for Gene Therapy: Key Considerations for the AAV Analytical Lifecycle
DESCRIPTION:AAV vectors offer clear benefits for gene therapy\, and continued advances in technology have increased target specificity\, improved potency\, and intensified production efficiency.  Even with significant attention early in development\, analytical activities for gene therapy often land on the critical path.   \nThis webinar provides considerations for phase-appropriate AAV characterization and release activities from pre-clinical to late-phase products. Early-stage analytical topics will address how to leverage platform analytics\, client-specific methods and transfers\, formulation verifications\, tox material testing\, and stability. Late-stage focus will review continued development activities\, timing of method validation\, IPC verifications\, and data trending. We will discuss potential challenges in validation of late-stage analytics for PPQ and late-phase testing and paths for maturation of platform and product-specific analytics.
URL:https://thebiocalendar.com/event/streamline-the-critical-path-for-gene-therapy-key-considerations-for-the-aav-analytical-lifecycle/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/11/12-02-25-Catalent-eBlast-700x200-1.png
END:VEVENT
END:VCALENDAR